Clinical trials: Lung Fibrosis Interstitial
Idiopathic Pulmonary Fibrosis
Homecare Integral Support Program for IPF Patients
Homecare patient support program especially designed for covering IPF patient needs, implemented for 12 months, for improving quality of life
- Trial name
- PSPi-IPF (NCT05173571)
- Testing
- Comprehensive patient support program (educational, physiotherapy, nutritional, emotional)
- Where
- Spain
- Volunteers
- 95 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Idiopathic Pulmonary Fibrosis, Lung Transplant; Complications
Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis
The diagnosis of idiopathic pulmonary fibrosis (IPF) is currently one of the most common diagnoses for patients under evaluation for lung transplantation.
- Trial name
- NCT03258801
- Where
- Austria
- Sponsor
- Dr. Christopher Lambers
Idiopathic Pulmonary Fibrosis (IPF)
Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）
This study was divided into two parts. The first part was a dose escalation study: a open label dose escalation design was used to evaluate the safety, tolerance and pharmacokinetic characteristics of ZSP1603 in IPF patients.
- Trial name
- NCT05119972
- Testing
- ZSP1603
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Interstitial Lung Diseases, Sarcoidosis
The Occurence of Inflammation and Oxidative Stress in Lung Diseases
Reactive oxygen species (ROS) are suggested to play a pivotal role in ILD. Little is known, however, about the endogenous antioxidant levels in ILD that can offer protection against ROS.
- Conditions
- Interstitial Lung Diseases, Sarcoidosis, Idiopathic Pulmonary Fibrosis, COPD
- Trial name
- NCT00512967
- Where
- Netherlands
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Interstitial Lung Disease, Interstitial Fibrosis
Integrating Molecular, Genomic, Morphology and Environmental Features to Improve Precision Diagnosis and Treatment in Interstitial Lung Diseases (PRECISION-ILD)
Integrating Molecular, Genomic, Morphology and Environmental Features to Improve Precision Diagnosis and Treatment in Interstitial Lung Diseases (PRECISION-ILD) Background: Interstitial Lung Diseases (ILDs) are a heterogeneous…
- Trial name
- PRECISION-ILD (NCT05998512)
- Testing
- Observational register
- Where
- 3 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Idiopathic Pulmonary Fibrosis
Conducting Airways in Lung Fibrosis (VACFI)
The purpose of this study is to determine whether extension of the conducting airways into the distal lung, or bronchiolization, occurs early in the course of Idiopathic Pulmonary Fibrosis, a disease wherein normal lung…
- Trial name
- VACFI (NCT01777373)
- Where
- France
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Fibrosis
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Idiopathic pulmonary fibrosis (IPF) is a long-term lung disease that affects an individual's ability to breathe. In this randomized, double-blind, placebo-controlled trial, we assigned patients with idiopathic pulmonary fibrosis…
- Trial name
- PANTHER-IPF (NCT00650091)
- Testing
- N-acetylcysteine (NAC)
- Where
- 26 sites in United States
- Volunteers
- 264 people
- Sponsor
- Duke University
Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of…
- Trial name
- NCT04968574
- Testing
- taladegib
- Where
- 24 sites in Australia, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Endeavor Biomedicines, Inc.
Idiopathic Pulmonary Fibrosis
This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.
The primary objective is to investigate safety and tolerability of BI 1015550 in patients with IPF. The secondary objectives are to evaluate the pharmacokinetics (PK) of BI 1015550 in patients with IPF.
- Trial name
- NCT03422068
- Testing
- BI 1015550
- Where
- 11 sites in Denmark, Finland and 5 more
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Fibrosis, Anxiety
Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF
The purpose of the study is to assess efficacy and safety of a digital cognitive behavioural therapy for patients with pulmonary fibrosis on anxiety.
- Trial name
- COMPANION (NCT05330312)
- Testing
- Digital cognitive behavioral therapy
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- Vicore Pharma AB
Idiopathic Pulmonary Fibrosis
Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)
The overall aim of this study is to develop a test that predicts the prognosis of IPF (Idiopathic Pulmonary Fibrosis) and which could be used to determine whether new treatments for IPF are likely to work.
- Trial name
- PROFILE (NCT01134822)
- Where
- United Kingdom
- Volunteers
- 330 people
- Sponsor
- University of Nottingham
Asthma, COPD
Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)
This is a research study where researchers are collecting blood to evaluate the genetic characteristics of individuals with chronic lung diseases, including asthma, COPD (chronic obstructive pulmonary disease), interstitial lung…
- Conditions
- Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis
- Trial name
- Q-BC (NCT00504361)
- Where
- Qatar
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
Pulmonary diseases are increasingly important causes of morbidity and mortality in the modern world. Sildenafil, an orally administered a phosphodiesterase type 5 (PDE-5) inhibitor, targets the nitric oxide (NO) pathway.
- Trial name
- NCT01382368
- Testing
- Sildenafil
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Idiopathic Pulmonary Fibrosis, Healthy
Determination of Functional Exercise Capacity, Respiratory Muscle Endurance in Idiopathic Pulmonary Fibrosis
There are not enough studies in the literature comparing functional capacity, respiratory functions and muscle strength of IPF patients with healthy individuals.
- Trial name
- NCT06668051
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Pulmonary Fibrosis
Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
The general purpose of this trial is to investigate the efficacy and safety of 4 dose strategies of BIBF 1120 treatment for 12 months, compared to placebo in patients with idiopathic pulmonary fibrosis.
- Trial name
- NCT00514683
- Testing
- low dose BIBF1120 once daily, low dose BIBF 1120 twice daily, intermediate dose BIBF 1120 twice daily
- Where
- 92 sites in Argentina, Australia and 23 more
- Volunteers
- 432 people
- Sponsor
- Boehringer Ingelheim
Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep
The purpose of this study is to investigate the effect of travelling to moderate altitude and of nocturnal oxygen therapy during a stay at moderate altitude on breathing and sleep of patients with pulmonary hypertension or with…
- Trial name
- NCT02150616
- Testing
- Moderate altitude sojourn, Low altitude sojourn, Oxygen
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Lung Diseases, Interstitial Lung Disease
Effects of Exercise Training on Respiratory Performance in Patients With Fibrosing Interstitial Lung Diseases
The current study recruited patients with fibrosing interstitial lung diseases (f-ILD) whatever was the underlying pathology. The investigators aimed to compare the effects of aerobic exercises for lower limbs (LL) versus upper…
- Conditions
- Lung Diseases, Interstitial Lung Disease, Fibrosis Lung
- Trial name
- ET-fILD (NCT05227443)
- Testing
- Exercise aerobic training, Upper, lower and breathing (ULB) exercise
- Where
- Egypt
- Volunteers
- 31 people
- Sponsor
- Alexandria University
Idiopathic Pulmonary Fibrosis
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Idiopathic pulmonary fibrosis
- Trial name
- NCT05016817
- Testing
- AlloRx
- Where
- Antigua and Barbuda
- Volunteers
- 20 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Interstitial Fibrosis, Kidney Transplant; Complications
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard…
- Conditions
- Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection
- Trial name
- NCT05285878
- Testing
- Fingolimod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a type of scarring (fibrotic) lung disease. Reduced exercise capacity is a key symptom experienced by patients.
- Trial name
- BEET-IPF (NCT06488638)
- Testing
- nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust